DIANTHUS THERAPEUTICS INC. - COMMON STOCK

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

08 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

28 Jun 2024 11:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

12 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

30 May 2024 16:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

09 May 2024 16:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

08 May 2024 16:30:54 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 16:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

11 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

21 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

07 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire